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S U M M A R Y
Objective: To assess the epidemiological and microbiological characteristics of pneumococcal acute otitis
media (AOM) in children in Brasov, Central Romania, before the introduction of pneumococcal conjugate
vaccine (PCV) into the routine national immunization program.
Methods: All AOM patients aged <5 years who underwent tympanocentesis or presented with purulent
otorrhea of 24 h duration during 2009–2011 were enrolled.
Results: Two hundred and twelve consecutive AOM patients had a middle ear ﬂuid (MEF) culture
performed; 99 (46.6%) episodes occurred in patients <12 months of age. One hundred and eleven (52.4%)
episodes were culture-positive. Tympanocentesis was performed in 142 patients and spontaneous
otorrhea cultures in 70 patients. Overall, 114 pathogens were recovered: Streptococcus pneumoniae was
the most common isolate (81 isolates, 70.3% of all culture-positive episodes), followed by non-typeable
Haemophilus inﬂuenzae (26, 20.7%), Streptococcus pyogenes (5, 4.5%), and Moraxella catarrhalis (2, 1.8%).
Antibiotic susceptibility and serotyping were performed for 48 (59.3%) S. pneumoniae isolates: 45 (93.8%)
were non-susceptible to penicillin (minimal inhibitory concentration (MIC) 2.0 mg/ml in 24, 53.3%) and
37 (77.1%) isolates had ceftriaxone MIC values 0.5 mg/ml (16 with MIC >2.0 mg/ml). S. pneumoniae
non-susceptibility rates to trimethoprim–sulfamethoxazole, erythromycin, and clindamycin were
75.0%, 58.3%, and 35.4%, respectively. All isolates were susceptible to chloramphenicol. Multidrug
resistance was found in 33 (68.7%) isolates. The most common S. pneumoniae serotypes were 19F (14,
29.2%), 6B (8, 16.7%), 23F (8, 16.7%), and 14 (6, 12.5%). Serotype 19A was found in three (6.2%) patients
and 6A in two (4.1%). Non-PCV13 serotypes represented six (12.6%) of all serotypes (four of them non-
susceptible to penicillin). Thirty-six (75.0%) isolates were potentially covered by PCV7, 37 (77.0%) by
PCV10, and 42 (87.5%) by PCV13.
Conclusions: (1) S. pneumoniae was the most prevalent pathogen, with frequent antibiotic resistance and
multi-resistance patterns; (2) most pneumococcal AOM and multidrug-resistant episodes could be
prevented by PCVs.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Acute otitis media (AOM) is the most frequent bacterial disease
of childhood, affecting millions of children worldwide and
remaining a major public health problem.1–3 The most common
causative agents in AOM are Streptococcus pneumoniae, non-
typeable Haemophilus inﬂuenzae (NTHi), Moraxella catarrhalis, and
Streptococcus pyogenes.4–8 Together, S. pneumoniae and NTHi
account for 60–80% of the AOM pathogens.9 Antibiotic resistance* Corresponding author.
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http://dx.doi.org/10.1016/j.ijid.2013.02.002is high in pneumococcal AOM, with penicillin- and amoxicillin-
non-susceptible strains accounting for 30–70% of cases.10–16 The
most commonly encountered S. pneumoniae serotypes in AOM are
6A, 6B, 14, 19A, 19F, and 23F.15,16 The highest antibiotic non-
susceptibility is found in vaccine serotypes 6A, 6B, 9 V, 14, 19A,
19F, and 23F.11,12,15,16
Information on antibiotic resistance patterns and serotype
distribution of S. pneumoniae isolates in infants and young children
in Romania is limited. In a multinational study, 42% of S.
pneumoniae AOM isolates from Romania were intermediately or
fully resistant to penicillin.17 In three studies investigating
pneumococcal mucosal and invasive disease isolates in HIV-
negative and HIV-positive infants and children in northeasternses. Published by Elsevier Ltd. All rights reserved.
Table 1
Acute otitis media microbiology of 212 episodes (111 culture-positive) during
2009–2011
Pathogen No. of episodesa
Streptococcus pneumoniae 78 (70.3)
Haemophilus inﬂuenzae 23 (20.7)
Streptococcus pyogenes 5 (4.5)
Moraxella catarrhalis 2 (1.8)




a The percentage of all culture-positive episodes is given in parenthesis.
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multidrug-resistant (MDR) organisms were reported.18–20 Recent-
ly, high rates of colonization with S. pneumoniae (reaching 71% in
children 13–24 months of age) accompanied by high resistance
rates to most of the commonly used antibiotic drugs were reported
among healthy and sick infants and children <5 years old in central
Romania.21
Active and continuous surveillance of the microbiology and
antibiotic susceptibility patterns of AOM pathogens in Romania is
important, particularly during the period preceding the introduc-
tion of pneumococcal conjugate vaccine (PCV). The aims of the
present study were to assess: (1) the overall distribution of
otopathogens and their antibiotic resistance patterns; and (2) PCV
coverage of S. pneumoniae middle ear ﬂuid (MEF) isolates in Brasov,
central Romania, during 2009–2011.
2. Patients and methods
We conducted a prospective epidemiological study between
January 1, 2009 and December 31, 2011, at the Children’s Hospital
of Brasov, in the central part of Romania. Brasov has a population of
400 000 inhabitants and the hospital is the only medical center
providing medical care for infants and children in the city. The
study protocol was approved by the institutional review board of
the University of Transilvania, Brasov. Informed consent was
obtained from the legal guardians of all children.
2.1. Patients and procedures
The study patients were infants and children aged <5 years
diagnosed with AOM by a pediatrician, family physician, or
otolaryngologist. The diagnosis was done when the patients
presented with: (1) symptoms and physical ﬁndings consistent
with AOM (fever, irritability, tugging of the ear, and redness and
bulging of the tympanic membrane with blurring of its anatomic
landmarks); (2) acute illness lasting 7 days. Bulging of the
tympanic membrane (in addition to clinical symptoms of AOM)
was present in all cases where a tympanocentesis was
performed.
Culture specimens were obtained by either tympanocentesis or
collection of pus from draining the ears (if lasting 24 h before
enrollment). Patients with tympanostomy tubes were excluded
from the study. In all episodes, we collected information on the
patient’s age, sex, the type of specimen (tympanocentesis or
draining pus), and the patient’s AOM history and recent antibiotic
treatment. Data were obtained from the medical records of the
hospital, clinical medical chart, or parent interview. None of the
patients had been immunized with a PCV before enrollment.
Tympanocentesis was performed by the study otolaryngologist
(AM) as previously described.7,12
2.2. Bacteriology
Swabs of MEF aspirates were placed in MW173 Amies transport
medium (Transwab; Medical Wire and Equipment), plated
immediately on trypticase agar containing 5% sheep blood and
5 mg/ml gentamicin, and on chocolate agar, and incubated at 35 8C
for 48 h in a 5% enriched CO2 atmosphere. Identiﬁcation,
serotyping, and testing of antimicrobial susceptibility to penicillin
and ceftriaxone (by E-test, PDM Epsilometer, AB Biodisk, Solna,
Sweden) and erythromycin, clindamycin, chloramphenicol, and
trimethoprim–sulfamethoxazole (TMP–SMX) (by disk diffusion)
were performed as described elsewhere, in accordance with the
Clinical and Laboratory Standards Institute (CLSI) recommenda-
tions.22 Non-susceptibility to 3 antibiotic classes was considered
multidrug resistance (MDR). Serotyping was done by quellungreaction.23 The organisms were sub-cultured and stored at 70 8C
at the Microbiology Laboratory of the Children’ Hospital of Brasov
and were further transported by air to the Pediatric Infectious
Disease Unit Laboratory of the Soroka University Medical Center,
Beer-Sheva, Israel, where all antimicrobial susceptibility testing
and serotyping was carried out.
S. pneumoniae isolates were considered susceptible to penicillin
if the minimal inhibitory concentration (MIC) values were
0.06 mg/ml, intermediate if penicillin MIC values were between
0.125 mg/ml and 1.0 mg/ml, and resistant if MIC values were
2.0 mg/ml. Ceftriaxone intermediate resistance was deﬁned by
MICs values between 0.5 and 1.0 mg/ml, and high resistance by
MICs values >2.0 mg/ml.
2.3. Statistical analysis
Data were recorded using Microsoft Access ofﬁce software. The
statistical analysis was performed using SPSS 17.0 software.
Contingency table analysis for comparing rates between un-
matched samples was performed using the Chi-square test or
Fisher’s exact test, as appropriate. The Student independent
samples t-test was used to compare continuous variables. The
percentages of serotype coverage were calculated and compared
between PCV7 (serotypes 4, 6B, 9 V, 14, 18C, 19F, and 23F), PCV10
(PCV7 plus serotypes 1, 5, and 7F), and PCV13 (PCV10 plus
additional serotypes 3, 6A, and 19A). All tests were considered
signiﬁcant if p-values were <0.05.
3. Results
During the study period, 212 consecutive infants and young
children <5 years of age were enrolled. There were 120 (56.6%)
males. The mean age ( standard deviation) was 18.0  14.2 months.
Ninety-nine (46.6%) episodes occurred in patients <12 months old
and 136 (64.2%) episodes occurred in children <2 years old. One
hundred and eleven samples (52.4%) were culture-positive. Children
with culture-positive MEF were older than children with culture-
negative MEF (20.6  15.2 months vs. 15.4  12.6 months, p = 0.008).
Tympanocentesis was recorded in 142 patients and spontane-
ous otorrhea in 70 patients. No differences were recorded in the
proportions of spontaneous perforation between children with
culture-positive and children with culture-negative MEF (38/111,
34.2% vs. 32/101, 31.7%, p = 0.7).
A total of 114 isolates (76 from tympanocentesis and 38 from
spontaneous otorrhea specimens) were recovered. S. pneumoniae
was the most common isolate (81 isolates, 78 episodes, 71.1% of all
pathogens recovered and 70.3% of all culture-positive episodes),
followed by NTHi (26, 23; 22.8% and 20.7%), Streptococcus
pyogenes (5, 5; 4.4% and 4.5%) and Moraxella catarrhalis (2, 2;
1.8% and 1.8%) (Table 1). In three patients (1.4% of all episodes),
both S. pneumoniae and NTHi were isolated. No differences were
recorded in the percentages of S. pneumoniae recovered from
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ous otorrhea (55/76, 72.4% vs. 26/38, 68.4%, p = 0.7). No
differences were recorded in the mean age at diagnosis of
patients with S. pneumoniae AOM compared with patients with
AOM caused by other etiologic agents (18.16  7.08 vs.
24.59  18.37 months, p = 0.1).
Reliable information on prior antibiotic treatment (during the
24 h preceding AOM diagnosis) was available for 68/111 (60.2%)
culture-positive patients; 29/68 (42.6%) culture-positive patients
received previous antibiotic treatment compared with 34/101
(33.7%) culture-negative patients (p = 0.24). The representation of
S. pneumoniae was higher in patients previously untreated with
antibiotics compared with patients treated with antibiotics (28/39,
71.7% vs. 14/29, 48.3%, p = 0.03).
Antibiotic susceptibility testing and serotyping were performed
for 48/81 (59.3%) S. pneumoniae isolates. Forty-ﬁve (93.8%) S.
pneumoniae isolates were non-susceptible to penicillin; 24 (53.3%)
had MIC values 2.0 mg/ml. Six isolates had a penicillin MIC value
of 16.0 mg/ml, one had a MIC of 8.0 mg/ml, and three had a MIC of
4.0 mg/ml. Thirty-seven (77.1%) isolates had ceftriaxone MIC
values 0.5 mg/ml (32.0 mg/ml for ﬁve isolates, 4.0 mg/ml for
nine isolates, 2.0 mg/ml for one isolate, and 1.0 mg/ml for one
isolate). The non-susceptibility rates to TMP–SMX, erythromycin,
and clindamycin were 36/48 (75%), 28/48 (58.3%), and 17/48
(35.4%), respectively. All isolates were susceptible to chloram-
phenicol. Resistance to 1 antibiotic class was found in 44 (91.7%)
and MDR in 33 (68.7%) S. pneumoniae isolates. No differences were
recorded in the resistance patterns to antibiotics of S. pneumoniae
recovered from tympanocentesis versus the isolates recovered
from culture of spontaneous otorrhea.
The most common S. pneumoniae serotypes were: 19F (14,
29.2%), 6B (8, 16.7%), 23F (8, 16.7%), and 14 (6, 12.5%) (Table 2).
Serotype 19A was found in three (6.2%) patients and 6A in two
(4.1%) patients. The non-PCV13 serotypes represented six (12.6%)
of all serotypes, and four of them were non-susceptible to
penicillin. Six (75%) of the eight serotype 23F isolates had a
penicillin MIC of 16.0 mg/ml and a ceftriaxone MIC value of
32.0 mg/ml; 3/14 (21.4%) serotype 19F isolates had a penicillin
MIC value of 4.0 mg/ml and one had a penicillin MIC value of
8.0 mg/ml. The MDR isolates included, in descending order,
serotypes 19F, 6B, 23F, 19A, and 6A. Of the 14 serotype 19F
isolates, 13 (92.9%) were non-susceptible to penicillin, erythro-
mycin, and TMP–SMX, and 9/13 (69.1%) also to clindamycin. All
eight serotype 6B isolates were non-susceptible to penicillin,
erythromycin, TMP–SMX, and clindamycin. All eight serotype 23F
isolates were non-susceptible to penicillin, erythromycin, and
TMP–SMX, and 5/8 (62.5%) also to clindamycin. All three serotype
19A isolates were non-susceptible to penicillin, erythromycin,Table 2
Streptococcus pneumoniae serotype distribution (in decreasing frequency) for 48
acute otitis media episodes
Serotype No. episodes (%) MDR
19F 14 (29.2) 13 (92.9%)
23F 8 (16.7) 8 (100%)
6B 8 (16.7) 8 (100%)
14 6 (12.5) -
19A 3 (6.2) 3 (100%)
6A 2 (4.1) 1 (50%)
22F 2 (4.1) -
9V 1 (2.1) -
34 1 (2.1) -
9A 1 (2.1) -
7F 1 (2.1) -
Omni-negative 1 (2.1) -
Total 48 33 (68.7%)
MDR, multiple drug resistance.and TMP–SMX, and 2/3 (66.7%) also to clindamycin. One of the two
serotype 6A isolates was non-susceptible to penicillin, erythro-
mycin, TMP–SMX, and clindamycin.
Of the 48 tested S. pneumoniae serotype isolates, 36 (75.0%) are
included in PCV7, 37 (77.0%) in PCV10, and 42 (87.5%) in PCV13.
4. Discussion
The present study aimed to provide baseline data on the
contribution of S. pneumoniae to the etiology of AOM in Romania.
We also analyzed the resistance patterns to antibiotics and the
serotype distribution of this pathogen before the introduction of
universal PCV immunization in Romania.
Our main ﬁndings were: (1) infants and young children with
culture-positive AOM were older compared with those with
culture-negative AOM; (2) S. pneumoniae was the dominant
etiologic agent, being isolated in 74.3% of the culture-positive
patients; (3) most of the isolates were resistant to penicillin,
erythromycin, and TMP–SMX, and MDR was very common; (4) the
current PCVs could potentially prevent most of the pneumococcal
AOM in the region. The present study may provide a basis for
follow-up and monitoring of AOM etiology and resistance patterns
after the introduction of PCV into the national program.
In the Brasov area, we recently reported that of 205
pneumococcal nasopharyngeal isolates obtained from infants
and children <5 years of age (attending daycare centers,
immunization clinics, or visiting the pediatric emergency room
of the hospital for different acute illnesses, as well as healthy
patients admitted to the surgery department for elective
procedures), 83% were non-susceptible to penicillin and 18% were
non-susceptible to ceftriaxone, of which 40.5% and 16% were
highly-resistant to penicillin and ceftriaxone, respectively.21 The
non-susceptibility rates to erythromycin, TMP–SMX, tetracycline,
and clindamycin were also high (>50% for each antibiotic) and
MDR was found in 67% of isolates. The most common pneumo-
coccal serotypes isolated were 23F, 6B, 19F, 14, 6A, and 19A, and
the potential coverage by PCV7, PCV10, and PCV13 was 66%, 74%,
and 80%, respectively. This is consistent with the AOM ﬁndings in
the current study.
The major limitation of this study derives from the small
number of pneumococcal isolates evaluable for antibiotic
susceptibility testing and serotyping. On the other hand, the data
presented here from MEF cultures performed in AOM patients
diagnosed and treated at the Brasov Children’s Hospital are
additional to previously published information on the pneumo-
coccal carriage in patients enrolled from daycare centers and
immunization clinics in the city of Brasov and also from the
emergency room and surgery department of the hospital (which is
the only referral pediatric hospital in the whole area and is the
only site where MEF and nasopharyngeal cultures are per-
formed).21 Therefore, we are convinced that these two studies
from Brasov provide an up-to-date and reliable picture of the local
pneumococcal burden in infants and young children and the
antibiotic susceptibility, serotype distribution, and potential
serotype coverage by PCVs in the city of Brasov and the
surrounding areas. At the present time, additional limited data
from nasopharyngeal and MEF pneumococcal isolates obtained
from infants and young children are available from the
northeastern (Iasi) and southern (Bucharest) areas of the country
and provide a similar picture in terms of colonization burden,
extremely high antibiotic resistance rates, serotype distribution,
and potential PCV coverage.17–21,24
The presented data, together with the additional data from
northeastern Romania, raise major concerns regarding the
unskilled used of antibiotics in this country, leading to high
resistance. Furthermore, the high rate of resistance is of concern in
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treatment of AOM.
Faced with the alarming resistance data presented in this study,
an intervention program including a major reduction in antibiotic
use, combined with introduction of routine vaccination with PCVs,
is much needed in Romania. In France, Cohen et al.25 clearly
showed that the implementation of a national program of
reduction of inappropriate antibiotic use markedly contributed
to the efﬁcacy of PCV7 in reducing the carriage of penicillin-non-
susceptible pneumococci in children with AOM. In a study
evaluating the association between antibiotic use in the commu-
nity and the increase in antibiotic-resistant S. pneumoniae carriage
in Bedouin children aged <5 years in southern Israel from 1998 to
2005, Greenberg et al.26 examined all the antibiotic prescriptions
provided from two community primary pediatric clinics and
reported a decrease by 19% in the total annual prescription rates,
mainly as a result of a reduction in amoxicillin–clavulanate
prescriptions. Oral cephalosporins, erythromycin, and penicillin
prescription rates decreased signiﬁcantly as well, but azithromycin
prescription rates increased signiﬁcantly during the study period.
In parallel, the authors analyzed the S. pneumoniae nasopharyngeal
carriage in healthy children <5 years old from the same
communities and were able to demonstrate an increase in the
proportion of nasopharyngeal S. pneumoniae with penicillin MICs
1.0 mg/ml from 8% to 21% and signiﬁcant increases in resistance
to clindamycin, erythromycin, and tetracycline and also in
multidrug resistance. The authors suggested an association
between the increased carriage of MDR S. pneumoniae and the
increased azithromycin consumption, and cautioned that a
reduction in the total antibiotic use may not be sufﬁcient as long
as antibiotics with a high potential for the promotion of multidrug
resistance, like azithromycin, continue to be used widely.26
The introduction of the 7-valent conjugate PCV (PCV7) had a
major role in the reduction of invasive and mucosal disease rates
caused by S. pneumoniae and of the antimicrobial resistance of the
isolated organisms, and also, although less impressive, in the
reduction of nasopharyngeal colonization and AOM cases caused
by this pathogen.27–32 In our study, the good coverage of overall
pneumococcal serotypes and also of MDR pneumococcal isolates
by all PCVs, and in particular by PCV13 (87.5% and 100%,
respectively), are important and encouraging ﬁndings.
PCV7 was registered in Romania in September 2007, but is not
yet included in the routine immunization program for Romanian
infants and children. Initiation of a national immunization
program is urgently needed in order to achieve a reduction in
pneumococcal disease in general and of antibiotic-resistant and
MDR pneumococcal AOM in particular.
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